COVID-19 has undoubtedly caused a dramatic slowdown in deal activity globally. The life sciences sector has been more resilient than most but deal activity is significantly down versus 2019. As we look to a post-COVID-19 world, please join us as we ask our panel of strategic, private equity and venture capital leading deal makers to share their reflections on the impact COVID-19 has had on deal making in the life sciences sector and lessons learned and their perspectives on deal making and deal trends in the sector in a post-COVID-19 world.
- Startdatum / -uhrzeit:
- 16 July 2020, 4:00 PM BST
- Enddatum / -uhrzeit:
- 16 July 2020, 5:00 PM BST
Questions? Interested in hearing more about a certain topic? Submit your question or topic request to our team and we will do our best to address it during the roundtable. See you then!
Iqbal Hussain - Life Sciences Transactional Partner - Reed Smith
A.Maria Dahl - Head of Transactions: Oncology Business Development & Licensing - AstraZeneca
Edward de Nor - Executive Parter - GHO Capital
Johan Verbeeck - Vice President Business Development, Immunology - Janssen Pharmaceutical Companies of Johnson & Johnson
Laurence Barker - Partner and CBO - Dementia Discovery Fund SV Heath Investors
James West - Director - Results Healthcare